Dewpoint Therapeutics, Inc.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2025 | $77 M | No. 3 | $50 to $250 million | equity | SEC | |
| Jan 2022 | $150 M | No. 2 | $50 to $250 million | equity | SEC | |
| Jul 2020 | $77 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Dewpoint Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2026).
SEC Form D · Jul 2026
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jul 2026
That is all the official record says: Dewpoint Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Dewpoint Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 25 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Ameet Nathwani, M.D. | Executive officer | Jul 2026 |
| Isaac A. Klein, M.D., Ph.D. | Executive officer | Jul 2026 |
| Elisabeth A. Leiderman | Executive officer | Sep 2025 |
| Lori A. Escobedo | Executive officer | Sep 2025 |
| Ameet A. Nathwani, M.D. | Executive officer | Feb 2022 |
| Joel D. Sendek | Executive officer | Feb 2022 |
| Amir H. Nashat | Executive officer | Nov 2020 |
| Bruce H. Beutel | Executive officer | Nov 2020 |
| Ameet Nathwani, M.D. | Director | Jul 2026 |
| Amir H. Nashat, Sc.D. | Director | Jul 2026 |
| Anthony A. Hyman, Ph.D. | Director | Jul 2026 |
| Giuseppe A. Ciaramella, Ph.D. | Director | Jul 2026 |
| Mark A. Murcko, Ph.D. | Director | Jul 2026 |
| Olivier Brandicourt, M.D. | Director | Jul 2026 |
| Regina Barzilay, Ph.D. | Director | Jul 2026 |
| Richard A. Young, Ph.D. | Director | Jul 2026 |
| Srinivas Akkaraju, M.D., Ph.D. | Director | Jul 2026 |
| Steven H. Neier, Ph.D. | Director | Jul 2026 |
| Amir H. Nashat, Ph.D. | Director | Sep 2025 |
| Fabio H. Pucci, Ph.D. | Director | Sep 2025 |
| Guiseppe A. Ciaramella, Ph,D. | Director | Sep 2025 |
| Ameet A. Nathwani, M.D. | Director | Feb 2022 |
| Amir H. Nashat | Director | Feb 2022 |
| Giuseppe H. Ciaramella, Ph.D. | Director | Feb 2022 |
| Juergen A. Eckhardt, M.D. | Director | Feb 2022 |
| Olivier H. Brandicourt, M.D. | Director | Feb 2022 |
| Regina A. Barzilay, Ph.D. | Director | Feb 2022 |
| Srinivas H. Akkaraju, M.D., Ph.D. | Director | Feb 2022 |
| Giuseeppe H. Ciaramella, Ph.D. | Director | Nov 2020 |
| Jurgen A. Eckhardt, M.D. | Director | Nov 2020 |
| Oliver H. Brandicourt, M.D. | Director | Nov 2020 |
| Richard A Young, Ph.D. | Director | Nov 2020 |
| Srinivas H. Akkaraju, M.D. | Director | Nov 2020 |